Trends in Psychiatry and Psychotherapy
https://trends.org.br/article/doi/10.47626/2237-6089-2022-0599
Trends in Psychiatry and Psychotherapy
Review Article

The impact of inflammatory and metabolic markers on depression, anxiety, and cognition after COVID-19: a narrative review

Elton Jorge Bessa Diniz, Fulvio Alexandre Scorza, Fabrício Maués Santos Rodrigues, Claudia Berlim de Mello, Tatiana Carvalho de Souza Bonetti, Karina Ramalho Bortoluci, Jair de Jesus Mari

Downloads: 3
Views: 875

Abstract

Objectives
There has been growing concern about the long-term effects of coronavirus disease 2019 (COVID-19) on mental health. The biological factors common to psychiatric conditions and COVID-19 are not yet fully understood.

Methods
We narratively reviewed prospective longitudinal studies that measured metabolic or inflammatory markers and assessed psychiatric sequelae and cognitive impairment in individuals with COVID-19 at least 3 months after infection. A literature search identified three relevant cohort studies.

Results
Overall, depressive symptomatology and cognitive deficits persisted for up to 1 year after COVID-19; depression and cognitive changes were predicted by acute inflammatory markers, and changes in these markers correlated with changes in depressive symptomatology; female sex, obesity, and the presence of inflammatory markers were associated with more severe clusters of physical and mental health status in patients’ self-perceived recovery; and plasma metabolic profiles of patients continued to differ from those of healthy controls 3 months after hospital discharge, which were associated with widespread alterations in neuroimaging, reflecting issues with white matter integrity.

Conclusion
In individuals affected by COVID-19, prolonged exposure to stress and alterations in metabolic and inflammatory markers play a central role in psychiatric sequelae and cognitive deficits in the long term.

Keywords

COVID-19; inflammation; metabolomics; depression; anxiety; cognitive impairmento propose the incorporation of psilocybin in the treatment of disordered eating behaviors, preliminary evidence supports the need for more rigorous clinical trials as an important avenue for future investigation.

Submitted date:
01/30/2023

Accepted date:
06/16/2023

6499c0dfa95395107c702593 trends Articles
Links & Downloads

Trends Psychiatry Psychother

Share this page
Page Sections